Cannabidiol (CBD) “shows similar efficacy in the severe paediatric epilepsies to other antiepileptic drugs”, states a new meta-study published by the journal Developmental Medicine & Child Neurology, and epublished by the National Institute of Health.”
“There are hundreds of compounds found in the marijuana plant, each contributing differently to the antiepileptic and psychiatric effects”, states the study’s abstract. “Despite considerable community interest in the use of CBD for paediatric epilepsy, there has been little evidence for its use apart from anecdotal reports, until the last year. ” Researchers note that “Three randomized, placebo-controlled, double-blind trials in Dravet syndrome and Lennox-Gastaut syndrome found that CBD produced a 38% to 41% median reduction in all seizures compared to 13% to 19% on placebo.”
Similarly, “CBD resulted in a 39% to 46% responder rate (50% convulsive or drop-seizure reduction) compared to 14% to 27% on placebo. CBD was well tolerated; however, sedation, diarrhoea, and decreased appetite were frequent.”
Researchers conclude that “CBD shows similar efficacy to established antiepileptic drugs.”
The study was conducted by researchers at the University of Otago in New Zealand, and the University of Melbourne, Austin Health and Royal Children’s Hospital and the Florey and Murdoch Children’s Research Institutes, all in Australia.